Latest Conference Articles

July 16th 2018, 6:04pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

July 15th 2018, 1:51am

PER® Annual Live Medical Crossfire: Hematologic Malignancies

With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.

July 15th 2018, 1:38am

PER® Annual Live Medical Crossfire: Hematologic Malignancies

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

July 15th 2018, 12:12am

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

July 14th 2018, 11:13pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.

July 14th 2018, 11:03pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

July 14th 2018, 10:02pm

PER® Annual Live Medical Crossfire: Hematologic Malignancies

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.

June 22nd 2018, 11:01pm

ESMO Gastrointestinal Cancers Congress

Results from the regorafenib dose optimization study (ReDOS) presented at the 2018 World Congress on GI Cancer established that the strategy of escalating regorafenib from 80 mg to 160 mg per day was superior to starting at a dose of 160 mg per day.

June 22nd 2018, 10:48pm

ESMO Gastrointestinal Cancers Congress

TAS-102 (trifluridine/tipiracil; Lonsurf) continued to show consistent benefits and safety in a real-world treatment setting for patients with refractory metastatic colorectal cancer.

June 22nd 2018, 10:36pm

ESMO Gastrointestinal Cancers Congress

Eileen M. O’Reilly, MD, speaks to the progress being made with immune therapies in pancreatic cancer.

June 22nd 2018, 10:27pm

ESMO Gastrointestinal Cancers Congress

Eileen O'Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

June 22nd 2018, 10:01pm

ESMO Gastrointestinal Cancers Congress

Richard S. Finn, MD, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California, Los Angeles, recaps recent second-line advancements in hepatocellular carcinoma.

June 22nd 2018, 9:11pm

ESMO Gastrointestinal Cancers Congress

Atezolizumab alone or in combination with cobimetinib failed to show superior overall survival compared with regorafenib for patients with chemorefractory metastatic colorectal cancer.

June 21st 2018, 10:49pm

ESMO Gastrointestinal Cancers Congress

TAS-102 (trifluridine/tipiracil; Lonsurf) provided a 31% reduction in the risk of death compared with placebo in patients with heavily pretreated metastatic or advanced gastric cancer.

June 21st 2018, 8:56pm

ESMO Gastrointestinal Cancers Congress

Second-line treatment with pembrolizumab (Keytruda) did not significantly improve overall survival or progression-free survival in patients with advanced or metastatic gastric or gastroesophageal junction cancer with a PD-L1 combined positive score ≥1.

June 21st 2018, 7:02pm

ESMO Gastrointestinal Cancers Congress

George P. Kim, MD, Orange Park Medical Center, discusses the results of the PRODIGE 37 trial in patients with pancreatic cancer.

June 21st 2018, 7:02pm

ESMO Gastrointestinal Cancers Congress

George D. Demetri, MD, director, Center for Sarcoma and Bone Oncology, senior vice president, Experimental Therapeutics, Dana-Farber Cancer Institute, professor of Medicine, Harvard Medical School, discusses the use of larotrectinib in patients with TRK-fusion gastrointestinal (GI) cancers.

June 21st 2018, 12:44am

ESMO Gastrointestinal Cancers Congress

Thierry Conroy, MD, discusses the PRODIGE 24/CCTG PA.6 trial and shares his insight on future research with this treatment regimen.

June 21st 2018, 12:26am

ESMO Gastrointestinal Cancers Congress

TAS-120 demonstrated a clinically meaningful benefit with a manageable toxicity profile in patients with cholangiocarcinoma harboring FGFR2 gene fusions, including patients who had progressed on an FGFR inhibitor.

June 20th 2018, 11:33pm

ESMO Gastrointestinal Cancers Congress

Selective internal radiation therapy in combination with sorafenib (Nexavar) did not provide a significant survival improvement compared with sorafenib alone in patients with advanced hepatocellular carcinoma.